Publication: 3823

Publication: 3823

Analysis of Transplant-eligible Patients (Pts) Who Received Front-line Daratumumab (DARA)-based Therapy for Treatment of Newly Diagnosed Multiple Myeloma (NDMM) With High-risk Cytogenetic Abnormalities (HRCA) in the GRIFFIN (AFT-29) and MASTER Studies

URL

Google Scholar

Citation:: Blood vol 140 (suppl 1) 10144–7

Meeting Instance:: ASH 2022
Year:: 2022
Type:: Abstract
Sub type:: Poster Discussion
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4081

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Jansen
Grants:

Corr. Author:
Authors:: Natalie S. Callander Rebecca Silbermann Jonathan L. Kaufman Kelly N. Godby Jacob Laubach Timothy Schmidt Douglas W. Sborov Eva Medvedova Brandi Reeves Binod Dhakal Cesar Rodriguez Saurabh Chhabra Ajai Chari Susan Bal Larry D. Anderson Jr. Bhagirathbhai R Dholaria Nitya Nathwani Parameswaran Hari Nina Shah Naresh Bumma Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Thomas S. Lin Smith Giri Luciano J. Costa Paul G. Richardson Saad Z Usmani Peter M. Voorhees

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TN008, LAPS-TX011, LAPS-TX035, LAPS-UT003, LAPS-WI013, LAPS-WI020, NC002, NE003, NEWMEXICO, NY021, OR013

Study
Multiple Studies, or Legacy Studies in Alliance Study:: AFT-29 (GRIFFIN), MASTER
Phases:: 2

Keywords: